Authors: Suster, Saul; Moran, Cesar

Source: Expert Review of Molecular Diagnostics, Volume 5, Number 5, September 2005 , pp. 715-723(9)

Publisher: Expert Reviews

Abstract:

Malignant mesothelioma of the pleura is a relatively rare neoplasm that has been estimated to account for 20 deaths per million males per year in North America and Europe. A causative association has been well established with asbestos exposure. Paradoxically, the incidence of this tumor continues to rise despite public efforts to reduce, contain or eliminate exposure to asbestos fibers over the past few decades. Another paradoxical feature of the disease is that the majority of malignant mesotheliomas represent morphologically low-grade, well-differentiated neoplasms, yet they follow a relentlessly aggressive and virtually uniformly fatal outcome. For this reason, identification of clinical, morphologic, immunohistochemical or molecular genetic parameters is of extremely limited value for prognostication. Surprisingly, for a disease that currently has no known cure, one of the major problems still lies in establishing the correct diagnosis. Diagnosis acquires a particular relevance in light of the medicolegal ramifications of this disease, and diagnosis of malignant mesothelioma is still fraught with difficulties. Despite the advances in modern diagnostic techniques, no specific markers or morphologic features exist that are exclusive to these tumors. Herein, the current status of malignant mesothelioma diagnosis is reviewed, including the possible contributions of modern molecular techniques for their diagnosis.

Keywords: electron microscopy; immunohistochemistry; malignant mesothelioma; molecular pathology

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737159.5.5.715

Publication date: 2005-09-01

More about this publication?

• Expert Review of Molecular Diagnostics provides expert reviews on molecular diagnostic technologies and applied pharmacogenomics in clinical medicine. Coverage includes molecular diagnostics, biomarkers, diagnostic technologies, microarrays and biochips, proteomics, pharmacogenomics, pharmacogenetics and personalized medicine.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• Free Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Biology ,  Genetics
• By this author: Suster, Saul ;  Moran, Cesar

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers